In this article top new infectious diseases and antimicrobial stewardship journal articles are identified. Here are our picks to share with you for November 2019.
Written By: Bassam Ghanem, Pharm.D., MS, BCPS
Edited By: Timothy P. Gauthier, Pharm.D., BCPS-AQ ID
Last updated: 5 December 2019
In this monthly column two pharmacists with advanced training in infectious diseases and antimicrobial stewardship identify top new journal articles published in the peer-reviewed scientific literature. Many of these are identified, shared, and discussed via Twitter. The authors can be found on Twitter @ABsteward (B.G.) & @IDstewardship (T.G.).
It is very hard to keep up with all of the new publications that come out each month. We hope this can assist people in identifying new articles of interest. We additionally hope it can serve as a place to come back to if you find something of interest and need a link to it.
1. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE) | CID
SUNSHINE RCT concluded that Fidaxomicin was well tolerated and demonstrated significantly higher rates of global cure compared with vancomycin, in children and adolescents with C. difficile infection.
2. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial | CC
Magic Bullet RCT did not demonstrate the noninferiority of colistin compared with meropenem, both combined with levofloxacin, in terms of efficacy in the empirical treatment of late VAP but demonstrated the greater nephrotoxicity of colistin.
3. Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity | CMI
This systematic review and meta-analysis concluded that vancomycin AUC:MIC performance was modest and inconsistent. Additionally it found the majority of studies included failed to demonstrate a relationship between AUC:MIC and positive clinical outcome.
4. Beta-lactam antibiotic versus combined Beta-lactam antibiotic and single-daily dosing regimens of aminoglycosides for the treatment of serious infections: a meta-analysis | IJAA
This systematic review and meta-analysis concluded that existing evidence suggests no added survival benefit from a single daily dosing regimen of an aminoglycoside when combined with beta-lactam antibiotics.
5. Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration | JAMA Netw Open
This cohort study found that patients received rifampin for diabetic foot osteomyelitis experienced lower rates of death and amputation than patients not treated with rifampin, which remained significant after adjustment for confounders.
Additional New & Notable Publications
Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in the community: an interrupted time-series analysis | Lancet ID
Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study | Lancet ID
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium | Lancet ID
Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP) | ICM
RECOMMENDED TO YOU